Eslami-S, Zahra http://orcid.org/0000-0002-3489-2479
Cortés-Hernández, Luis Enrique
Sinoquet, Léa
Gauthier, Ludovic
Vautrot, Valentin
Cayrefourcq, Laure
Avoscan, Laure
Jacot, William http://orcid.org/0000-0001-7834-061X
Pouderoux, Stéphane
Viala, Marie
Thomas, Quentin Dominique
Lamy, Pierre-Jean http://orcid.org/0000-0002-5750-159X
Quantin, Xavier
Gobbo, Jessica
Alix-Panabières, Catherine http://orcid.org/0000-0002-6401-2903
Article History
Received: 17 March 2023
Revised: 26 October 2023
Accepted: 1 November 2023
First Online: 16 November 2023
Competing interests
: CAP is one of the patent holders (US Patent Number 16,093,934) for detecting and/or characterizing circulating tumour cells. She received an honorarium from Menarini©. PJL is consultant in advisory boards for Agena Bioscience and AstraZeneca. He also received meeting travel support from Roche. WJ is in advisory boards Astra Zeneca, Eisai, BMS, Lilly France, Daiichi Sankyo, MSD, Novartis, Pfizer, Roche and Seagen and he received honoraria or payment from Astra Zeneca, Eisai, BMS, Lilly France, Daiichi Sankyo, MSD, Novartis, Pfizer, Roche and Seagen. WJ also received meeting travel support from Astra Zeneca, Novartis, Chugai Pharma, Pfizer, Eisai, Pierre Fabre, Glaxo Smithkline, Roche, Lilly France, Sanofi, and Aventis. The remaining authors declare no conflict of interest.
: All patients provided their written informed consent and were prospectively included in the ethics committee-approved ALCINA study (NCT02866149) that investigates the feasibility of assessing circulating tumour markers in blood in various early- or advanced-stage malignancies.